Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLQ | O75417 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | GPR183 | P32249 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1629699 | 0.89 | POLQ (0.45) | POLQCYP1A2CYP2D6CYP2C19RAB9A | |
| SCHEMBL12682526 | 0.86 | POLQ (0.50) | POLQCYP1A2CYP2D6CYP2C19RAB9A | |
| SCHEMBL15779383 | 0.85 | NOS3 (0.44) | POLQCYP1A2CYP2D6CYP2C19RAB9A | |
| SCHEMBL14992788 | 0.81 | HTR2A (0.44) | POLQCYP1A2CYP2D6CYP2C19RAB9A | |
| SCHEMBL27851289 | 0.81 | POLQ (0.43) | POLQCYP1A2CYP2D6CYP2C19RAB9A | |
| SCHEMBL18682191 | 0.81 | POLQ (0.47) | POLQCYP1A2CYP2D6CYP2C19RAB9A | |
| SCHEMBL11603196 | 0.80 | POLQ (0.48) | POLQCYP1A2CYP2D6CYP2C19RAB9A | |
| SCHEMBL15532382 | 0.80 | POLQ (0.52) | POLQCYP1A2CYP2D6CYP2C19RAB9A | |
| SCHEMBL22972987 | 0.79 | DAO (0.51) | POLQCYP2D6CTSSCTSK | |
| SCHEMBL22445529 | 0.79 | IDO1 (0.56) | POLQP2RX7CTSSCTSKSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100436440-C | Benzopyranone compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARM INC (US) | 2008-11-26 | — | — | CN | disclosed |
| US-20070015817-A1 | 4-((4-(2-pyrrolidinylethoxy)phenyl)methyl)-3-(4-(trifluoromethyl)phenyl)-7-hydroxychromen-2one, pharmaceutically acceptable salts thereof and methods of use therewith | MCKIE JEFFREY A | 2007-01-18 | — | — | US | disclosed |
| CN-1659159-A | Benzopyranone compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARM INC (US) | 2005-08-24 | — | — | CN | disclosed |
| EP-1497277-A1 | BENZOPYRANONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals, Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| US-20040092572-A1 | Benzopyranone compounds, compositions thereof, and methods of treatment therewith | NOVARTIS AG (CH) | 2004-05-13 | — | — | US | disclosed |
| WO-2003089422-A1 | BENZOPYRANONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-10-30 | — | — | WO | disclosed |
| US-6620838-B1 | Anticarcinogenic, antimestasis, and antiarthritic agents; osteoporosis and endometriosis treatment | SIGNAL PHARMACEUTICALS, INC. | 2003-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015817-A1 | 4-((4-(2-pyrrolidinylethoxy)phenyl)methyl)-3-(4-(trifluoromethyl)phenyl)-7-hydroxychromen-2one, pharmaceutically acceptable salts thereof and methods of use therewith | ESR2, CYP19A1, ESRRA | POLQ 2657/4885CYP1A2 95/4885CYP2D6 62/4885 |
| US-20040092572-A1 | Benzopyranone compounds, compositions thereof, and methods of treatment therewith | ESR2, ESRRA, ESR1 | POLQ 1895/4885CYP1A2 192/4885CYP2D6 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.